AMG 160; a half-life extended (HLE) bispecific T-cell engager (BITE®) antibody construct is discussed as is the future of immune therapy in CRPC.
Blaze Podcast Network
Managing Madrid
Emily Frisella and Mindy Musselman
Kat Adams
Stansberry Research
The A.V. Club
Prayan Goswami
Puja & Dilip
Rahul
Hockson Floin
don't worry if you don't have an account with us, we'll create one
